Pasar al contenido principal

RED TEMATICA ESPAÑOLA DE LA INTERACCION ENTRE EL METABOLISMO CELULAR Y EL MICROAMBIENTE EN HOMEOSTASIS Y ENFERMEDADES

RED2022-134927-T

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Redes Investigación /Redes Excelencia
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glioblastoma progression is hindered by melatonin-primed mesenchymal stromal cells through dynamic intracellular and extracellular reorganizations

  • Olmedo-Moreno, Laura
  • Panadero-Morón, Concepción
  • Sierra-Párraga, Jesús María
  • Bueno-Fernández, Rubén
  • Norton, Emily S.
  • Aguilera García, Yolanda
  • Mellado-Damas, Nuria
  • García-Tárraga, Patricia
  • Morales-Gallel, Raquel
  • Antequera-Martínez, María
  • Durán, Raúl V.
  • Ferrer-Lozano, Jaime
  • Escames, Germaine
  • García-Verdugo, José Manuel
  • Martín-Montalvo, Alejandro
  • Guerrero-Cázares, Hugo
  • Capilla-González, Vivian
Rationale: Glioblastoma (GBM) is the most fatal form of brain cancer and its treatment represents a persistent challenge. Mesenchymal stromal cells (MSCs) have been explored as therapeutic tools in cancer management owing to their tumor-homing abilities. However, their clinical application is limited due to the controversial role of MSCs in carcinogenesis. This study investigates how MSCs influence tumor behavior and explores the synergistic anticancer effects in combination with melatonin (Mel). Methods: Orthotopic and subcutaneous GBM xenograft mouse models were used to assess the antitumor effect of Mel pre-treated MSCs (MSCMel). Histological, immunohistochemical, and ultrastructural analyses were conducted to identify phenotypic changes in tumors. Through a set of in vitro assays, including direct and indirect co-cultures, dynamic single-cell tracking and tumorsphere assay, we explored the impact of MSCMel on primary and non-primary GBM cells. Transcriptomic profiling was used to identify genes and pathways modulated by this synergistic therapy. Results: MSCMel delayed tumor growth in mice and increased collagen deposition. Additionally, MSCMel showed enhanced capacity to prevent GBM cell migration compared to untreated MSCs. Molecular analysis identified genes and proteins related to cell migration, cytoskeletal dynamics and extracellular matrix remodeling in GBM cells exposed to MSCMel, including reduced vimentin expression. Finally, a genetic signature associated with the clinical outcomes of GBM patients was identified. Conclusions: Our study demonstrates that melatonin enhances the anticancer properties of MSCs, providing new insights into their interaction with GBM cells and tumor environment. These findings offer valuable guidance for advancing MSC-based therapies in clinical practice., This research was funded by the Institute of Health Carlos III, co-funded by Fondos FEDER (PI23/00315, PI20/00341 and CP19/00046 to VC-G) and the Asociación Española Contra el Cancer (IDEAS20051CAPI to VC-G). LO-M is supported by the Spanish Ministry of Science, Innovation and Universities (FPU19/04703). JMS-P was supported by the Consejería de Transformación Económica, Industria, Conocimiento y Universidades of Junta de Andalucia, co-funded by Fondos FEDER (POSTDOC/21/00424) and the Institute of Health Carlos III, co-funded by Eropean Union (CD23/00104). CP-M is supported by the Asociación Pablo Ugarte. RM-G is supported by the Asociación Española Contra el Cancer (PRDVA222457MORA). RV-D. was supported by Grant PID2021- 124251OB-I00 and Grant RED2022-134927-T funded by MICIU/AEI/10.13039/501100011033 and by ERDF/UE. AM-M is supported by the Ministerio de Ciencia e Innovación (PID2021-123965OB-100). HG-C is supported by the National Institute of Neurological Disorders and Stroke and internal Mayo Clinic funds. JMG-V was supported by the Valencian Council for Education, Culture, University and Employment (CIPROM/2023/053)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peroxynitrite is involved in the mitochondrial dysfunction induced by Sorafenib in liver cancer cells

  • Cruz-Ojeda, Patricia de la
  • Navarro-Villarán, Elena
  • Fuertes-Agudo, Marina
  • Mata, Ana
  • López-Lluch, Guillermo
  • Navas, Plácido
  • Cadenas, Susana
  • Casado, Marta
  • Muntané, Jordi
Sorafenib is a tyrosine kinase inhibitor (TKI) that belongs to the landscape of treatments for advanced stages of hepatocellular carcinoma (HCC). The induction of cell death and cell cycle arrest by Sorafenib has been associated with mitochondrial dysfunction in liver cancer cells. Our research aim was to decipher underlying oxidative and nitrosative stress induced by Sorafenib leading to mitochondrial dysfunction in liver cancer cells., We acknowledge the Instituto de Salud Carlos III (ISCIII) (PI19/01266 and PI22/00857) and Consejería de Salud y Familias (PI-0216-2020) for their financial support. Marta Casado and Marina Fuertes-Agudo were supported by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación 10.13039/501100011033 (PID2022-143192OB-I00; RED2022-134927-T). Susana Cadenas' lab is funded by the ISCIII grant PI23/01846 and Ana Mata is recipient of a predoctoral fellowship from the Comunidad de Madrid (PIPF-2022/SAL-GL-25516). P de la Cruz-Ojeda was supported by FPU predoctoral fellowship (FPU17/00026) and short-research stage program (EST19/01091) from Ministry of Education, Culture and Sports, and GEIVEX Mobility Fellowships 2020. Elena Navarro-Villarán was supported by the predoctoral i-PFIS IIS-enterprise contract in science and technologies in health (IFI18/00014) granted by the ISCIII. We thank the Biomedical Research Network Center for Liver and Digestive Diseases (CIBEREHD) and for Rare Diseases (CIBERER) founded by the ISCIII and co-financed by European Development Regional Fund “A way to achieve Europe” ERDF for their financial support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FGFR1 drives metabolic adaptation associated with temozolomide resistance in glioblastoma

  • Zarzuela, Laura
  • López-Cepero, Ignacio G.
  • Rattigan, Kevin M.
  • Reina-Bando, Ana
  • Martín-Montalvo, Jorge
  • Sierra-Párraga, Jesús M.
  • Sánchez-Escabias, Elena
  • Morillo-Huesca, Macarena
  • Oltra, Sara S.
  • Ceballos-Chávez, María
  • Capilla-González, Vivian
  • Moreno-Bueno, Gema
  • Murdoch, Piedad del Socorro
  • Reyes, José C.
  • Helgason, G. Vignir
  • Tomé, Mercedes
  • Durán, Raúl V.
Therapy resistance is a major limitation in therapeutic efficacy for glioblastoma (GBM) patients, positioning GBM among the deadliest tumor types. In this work, we have dissected resistance mechanisms in GBM, which resulted in the identification of FGFR1 pathway as a major controller of the signaling and metabolic rewiring associated to temozolomide (TMZ) resistance. Hence, in FGFR1-positive, p53 WT GBM cells, FGFR1 controls a p53-mediated cell cycle arrest to allow DNA repair in response to TMZ. FGFR1 also regulates a complete metabolic rewiring promoting lipid catabolism and preventing lipid peroxidation. Indeed, FGFR1 inhibition completely abolishes this signaling and metabolic reprograming, restoring sensitivity to TMZ. Our results also indicated a correlation of FGFR1 with poor prognosis in GBM patients, and validated the dual treatment with TMZ and FGFR1 inhibitors as an efficient strategy to induce tumor cell death in FGFR1-positive, p53 WT pre-clinical animal GBM models. These data position FGFR1 as a promising candidate for future clinical evaluation to limit therapy resistance to TMZ in FGFR1-positive GBM patients., Grants PID2021-124251OB-I00 and PID2024-156338OB-I00 funded by the Spanish MICIU/AEI/10.13039/501100011033/and by ERDF/EU (RVD, MTM). Grant RED2022-134927-T funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU (RVD, MTM) Grant PID2023-149538NB-I00 funded by the Spanish MICIU/AEI/10.13039/501100011033/and by ERDF/EU (JCR). Predoctoral FPU contract (FPU19/04914) from the Spanish Ministry of Universities (LZM). Predoctoral contract (PREDOC_00345) funded by PAIDI, Junta de Andalucia (IGLC). Predoctoral FPI contract (PRE2022-101357) funded by Spanish MICIU/AEI/10.13039/501100011033 and FSE+ (ARB). Predoctoral contract (PRDSE258639MART) from Asociación Española Contra el Cáncer (JMM). Grant PI23/00315 funded by Spanish Institute of Health Carlos III, co funded by Fondos FEDER (VCG). Grant CD23/00104 funded by Spanish Institute of Health Carlos III, co funded by Fondos FEDER (JMSP). Grant RyC2023-043933-I funded by Spanish Ministerio de Ciencia, Innovacion y Universidades (VCG). Grant A29754 funded by Cancer Research UK, UK (GVH). Grant CB16/12/00295 funded by Spanish CIBERONC (GMB). Grant PID2022-136854OB-I00 funded by MICIU/AEI/10.13039/501100011033 (GMB)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The V-ATPase/ATG16L1 axis drives membrane remodeling during epithelial morphogenesis

  • Baonza, Gabriel
  • Alfonso-Pérez, Tatiana
  • Quintana-Quintana, Carlos
  • Herranz, Gonzalo
  • Gordillo-Vázquez, Carmen
  • El Mazjoub, Yara
  • Escudero, Luis M.
  • Míguez, David G
  • Martí, Elisa
  • Martínez-Martín, Nuria
  • Martín-Belmonte, Fernando
Epithelial tubulogenesis shapes organs by transforming unpolarized epithelial cords into hollow tubes with central lumens. Posterior neural tube formation during secondary neurulation requires tightly coordinated membrane remodeling for de novo lumen formation and resolution, yet the role of autophagy in this process remains unclear. Autophagy operates through canonical and noncanonical pathways. While canonical autophagy is primarily degradative, the V-ATPase/ATG16L1-dependent Conjugation of ATG8 to Single Membranes (CASM) regulates LC3 lipidation on endocytic compartments. Using human neural tube organoids, MDCK cysts, and epithelial tube micropatterns selectively deficient in canonical or noncanonical autophagy, we demonstrate that CASM is essential for epithelial lumen resolution. Mechanistically, the V-ATPase/ATG16L1 axis coordinates junctional remodeling, phosphoinositide transitions, and Rab-dependent endocytic and recycling pathways to ensure single-lumen formation. These findings identify noncanonical autophagy as a spatially restricted membrane-remodeling mechanism that governs epithelial morphogenesis and reveal distinct, hierarchically balanced contributions of autophagy pathways during development., This work was supported by MICINN (PID2020-120367GB-I00; PID2023-151844OB-I00; RED2022-134927-T), Fondos FEDER investigación (Horizon-MSCA-2022-DN -101119504) and Fundación Ramon Areces (CIVP18A3904). HR22-00447 from ¨La Caixa¨, RTI2018-101586-A-I00, PID2021-126298OB-100 to N.M.-M. G.H. was supported by a FPI grant from MINECO (PRE2018-085662). G.B. was supported by a FPI grant from MINECO (PRE2021-098046). C.Q.-Q. was supported by a FPI grant from MINECO (PRE2023-001612). T.A.-P. was supported by a Juan de la Cierva grant from MICINN (IJC2018-038099-I), H2020-MSCA-IF−2019-897948, and Ayuda Investigador from AECC (INVES235112ALFO). The authors acknowledge support from the Spanish Ministry of Science, Innovation and Universities through the ‘Centro de Excelencia Severo Ochoa’ award to the Centro de Biología Molecular Severo Ochoa (CBM) (Grant No. CEX2021-001154-S). This work was also supported by the Ramón Areces Foundation., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001154-S)., Peer reviewed